SEC Filing Summary: Hemispherx Biopharma, Inc. (10-Q)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2004, for Hemispherx Biopharma, Inc. (Note: The input metadata referenced "AIM Immunotech Inc.", but the filing text explicitly identifies the registrant as Hemispherx Biopharma, Inc.). The company is a biopharmaceutical firm focused on developing nucleic acid technology, primarily for its lead product Ampligen(R) (treating ME/CFS and HIV) and its acquired product ALFERON N Injection(R) (treating genital warts).
Key Financial Metrics
| Metric (in thousands) | Q2 2004 | Q2 2003 | 6-Month 2004 | 6-Month 2003 |
|---|---|---|---|---|
| Total Revenues | $331 | $94 | $639 | $160 |
| Net Loss | $(5,956) | $(3,689) | $(13,997) | $(5,306) |
| Loss Per Share (Basic/Diluted) | $(0.14) | $(0.11) | $(0.33) | $(0.16) |
| Cash & Short-Term Investments | $9,433 | $5,259 | $9,433 | $5,259 |
| Total Assets | $18,933 | $13,404 | $18,933 | $13,404 |
| Accumulated Deficit | $(127,841) | $(113,843) | $(127,841) | $(113,843) |
| Long-Term Debt (Net) | $2,055 | $2,058 | $2,055 | $2,058 |
Note: Cash and short-term investments combined ($4,464 + $4,969) equals $9,433 as of June 30, 2004.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased significantly to $331,000 in Q2 2004 from $94,000 in Q2 2003. This was driven by ALFERON N sales ($289,000 vs. $60,000) and clinical treatment programs ($42,000 vs. $34,000).
- Increased Losses: Net loss widened to $5.96 million in Q2 2004 from $3.69 million in Q2 2003. The primary drivers were a $1.7 million increase in non-cash financing costs and higher production costs associated with preparing the New Brunswick facility.
- Financing Costs: Non-cash financing costs rose to $3.67 million in Q2 2004 from $1.97 million in Q2 2003, largely due to the amortization of debenture discounts and beneficial conversion features.
- Asset Acquisition: The company acquired the New Brunswick, NJ production facility from Interferon Sciences, Inc. (ISI) in March 2004, increasing property and equipment net value to $3.36 million.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current cash ($9.4 million) plus proceeds from recent warrant exercises (~$4.2 million) and an August 2004 private placement (~$7.5 million) will fund operations for the next 18 months. However, additional financing may be required.
- Clinical Progress:
- Ampligen (ME/CFS): Completed the double-blind segment of the Phase III AMP 516 trial. Data showed statistically significant improvement in exercise treadmill duration. An NDA filing is expected by end of 2004 or Q1 2005.
- Ampligen (HIV): Focused on the AMP 720 Phase IIb trial (Strategic Treatment Interruption). The AMP 719 trial is on hold.
- Strategic Partnership: A Memorandum of Understanding (MOU) with Fujisawa Deutschland GmbH grants them an exclusive option to market Ampligen in Germany, Austria, and Switzerland. An initial fee of ~$497,000 was received and recorded as deferred revenue. Future payments are contingent on regulatory filings and approvals.
- Risks:
- Regulatory Approval: No assurance that Ampligen will receive FDA or EMEA approval.
- Financing: Heavy reliance on convertible debentures and warrants creates significant dilution risk and non-cash charges.
- Manufacturing: Limited commercial-scale manufacturing experience; dependent on third parties for bottling and packaging.
- Legal: Pending appeal regarding defamation claims against Asensio & Company; product liability claims dismissed in June 2004.
Investor Verification Checklist
- Debt Conversion Terms: Verify the impact of anti-dilution provisions triggered by the August 2004 private placement on the conversion prices of outstanding debentures and warrants.
- Deferred Revenue Recognition: Confirm the timeline and conditions for recognizing the $497,000 deferred revenue from the Fujisawa MOU, specifically the December 31, 2004 reporting deadline.
- Cash Burn Rate: Assess if the projected 18-month runway is sufficient given the high non-cash financing charges and ongoing clinical trial costs.
- ALFERON N Sales Trajectory: Monitor the conversion of work-in-progress inventory to finished goods and the effectiveness of the new sales agreements (e.g., Engitech, LLC).
- Stockholder Approval: Note that stockholders approved the issuance of shares to comply with AMEX Section 713 on June 23, 2004, which reclassified a redemption obligation to equity.